Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. Persistent infection with HPV can lead to gynecological cancers – cervical, vulvar and vaginal – often taking years to develop. Prevention of HPV-related gynecologic cancers is possible with HPV vaccination and has already resulted in a significant decrease in the incidence of precancerous changes and cancer. Screening for cervical cancer with Pap smears and HPV testing is highly effective in detecting both precancerous changes and early cancers at a very treatable stage. In this lecture we will discuss the scope of HPV-related gynecologic cancers both in U.S. and worldwide, review the current data and recommendations regarding HPV vaccination, clarify the current recommendations regarding cervical cancer screening with Pap smears and HPV testing, and detail optimal treatment protocols for each type of cancer.
Internal Medicine Physicians, Physician Assistants, Residents, Advanced Practice Registered Nurses, Podiatrists, Pharmacists and all other interested healthcare providers.
- Discuss the scope of HPV-related Gynecologic Cancers both in US and worldwide.
- Review current recommendations for Cervical Cancer Screening in the US.
- Explain the impact of HPV vaccination on Cervical Dysplasia and Cervical Cancer.
- Examine current optimal treatment protocols for cervical, vulvar and vaginal cancers.
FACULTY AND DISCLOSURES:
Thomas Morrissey, M.D., F.A.C.O.G., F.A.C.S
Director of Gynecologic Oncology
Lynn Cancer Institute
Baptist Health South Florida
Clinical Affiliate Assistant Professor
Florida Atlantic University College of Medicine
Boca Raton, Florida
Thomas Morrissey, M.D., F.A.C.O.G., F.A.C.S., faculty for this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
John Rubin, M.D., director for this educational event, owns stock in AstraZeneca and Bristol Myers Squibb. He has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Kenneth Rosenthal, M.D., FACG, moderator for this educational event, indicated that he is on the Speaker’s Bureau for AbbVie, Inc. All of the relevant financial relationships listed for this individual has been mitigated.
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*
*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
ACCREDITATION STATEMENTS AND CREDITS
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1 credit hour, CE Broker Course #20-855339, by the Florida Boards of Medicine, Osteopathic Medicine and Physician Assistants.
This activity has also been approved for 1 credit for Nurse Practitioners, Nurses, Pharmacists and Pharmacy Techs, Athletic Trainers. Baptist Health South Florida CE Broker Provider #50-182.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Florida Board of Athletic Training
- 1.00 General certificate of attendance
- 1.00 Florida Board of Dietitians
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Nursing
- 1.00 Florida Board of Pharmacy